The FDA approved Qlosi, a low-dose, preservative-free eye drop for the treatment of presbyopia in adults, according to a press release from Orasis Pharmaceuticals.
“We are delighted that Qlosi is now FDA approved,” Elad Kedar, CEO of Orasis, told Healio. “Identifying the minimum effective dose was critical for us as we sought to bring a presbyopic solution which truly balances efficacy, safety and comfort — designed with the patient in mind.”
Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, formerly known as CSF-1, was evaluated in the phase 3 NEAR-1 and